What You Should Know:
– Siemens Healthineers, a leading global medical technology company operating in over 180 countries, is pioneering breakthroughs in healthcare through innovation and sustainability. With approximately 71,000 employees, Siemens Healthineers generated €21.7 billion in revenue in fiscal 2023.
– The company focuses on imaging, diagnostics, cancer care, and minimally invasive therapies, enhanced by advanced digital technology and artificial intelligence. Its mission includes improving access to healthcare for underserved communities and addressing the world’s most pressing diseases.
Advancing Liver Healthcare: Siemens Healthineers and SimonMed Imaging Collaborate for Early Detection and Diagnosis
SimonMed Imaging, one of the largest outpatient medical imaging providers and radiology practices in the United States, has integrated multiple ACUSON Sequoia ultrasound systems from Siemens Healthineers. This collaboration aims to enhance liver disease diagnosis and early detection through cutting-edge imaging technology. The integration includes advanced liver imaging capabilities, such as Ultrasound Derived Fat Fraction (UDFF), across several SimonMed locations, including three sites in Arizona (Litchfield, Apache Junction, and Laveen) and two in Nevada (Centennial and Southwest).
Key features of the ACUSON Sequoia ultrasound system include:
- Comprehensive liver assessment through quantification of tissue stiffness and hepatic fat in a single acquisition.
- Streamlined patient care pathways and reduced need for invasive interventions.
- Cost-effective screenings that improve accessibility and early detection.
The adoption of UDFF technology addresses the challenge of asymptomatic liver disease progression, which can lead to conditions such as steatohepatitis, fibrosis, and cirrhosis. UDFF offers personalized, accurate, and noninvasive screening, delivering clinical utility comparable to MR-PDFF but as a more cost-effective alternative to MRI.
With over 100 million Americans affected by metabolic-associated steatotic liver disease (MASLD), the American Liver Foundation highlights the importance of early detection. MASLD, the leading cause of chronic liver disease, is often reversible when identified early. Despite its prevalence, fewer than 5% of affected individuals are aware of their condition. The integration of Siemens Healthineers’ UDFF technology empowers clinicians with accessible tools for improved disease management and prevention of chronic liver disease.
“This collaboration represents a significant milestone in advancing liver healthcare through technological innovation,” said Travis Holles, head of the Americas for Siemens Healthineers Ultrasound business. SimonMed’s commitment to addressing the growing burden of liver disease underscores the potential of this partnership to transform patient outcomes by improving diagnostic accuracy and accessibility.
